2 years ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 3%
#137 out of 5550 analysts
Average Return
+13.4%
Win Rate
39%201 out of 519
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,180.61% | $10.52 | $134.72 | 2025-05-15 - 2026-05-14 | Buy |
Celcuity IncCELC | +1,169.12% | $9.23 | $117.14 | 2025-04-11 - 2026-04-10 | Buy |
Celcuity IncCELC | +1,128.63% | $9.29 | $114.14 | 2025-04-01 - 2026-03-31 | Buy |
Celcuity IncCELC | +728.28% | $12.59 | $104.28 | 2025-02-06 - 2026-02-05 | Buy |
Celcuity IncCELC | +667.94% | $13.35 | $102.52 | 2025-06-30 - 2026-06-29 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
3 years ago
AUTL
3 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Kazia Therapeutics LtdKZIA | 1 | Buy | $27.00 | +217.65% | Initiates Coverage On | 2 days ago |
Geron CorpGERN | 24 | Buy | $2.50 | +179.64% | Maintains | 4 days ago |
Artiva Biotherapeutics IncARTV | 12 | Hold | N/A | N/A | Downgrades | 5 days ago |
Recursion Pharmaceuticals IncRXRX | 28 | Buy | $8.00 | +98.51% | Reiterates | 13 days ago |
Nurix Therapeutics IncNRIX | 36 | Buy | $34.00 | +26.87% | Reiterates | 19 days ago |
Celcuity IncCELC | 28 | Buy | $134.00 | +93.84% | Maintains | a month ago |
IMMIX Biopharma IncIMMX | 2 | Buy | $30.00 | +290.63% | Maintains | a month ago |
Cartesian Therapeutics IncRNAC | 28 | Buy | $40.00 | +516.33% | Reiterates | a month ago |
Sarepta Therapeutics IncSRPT | 39 | Sell | N/A | N/A | Reiterates | a month ago |
Absci CorpABSI | 13 | Buy | $11.00 | -1.17% | Reiterates | a month ago |
Rocket Pharmaceuticals IncRCKT | 23 | Buy | $9.00 | +268.85% | Upgrades | 2 months ago |
Lyell Immunopharma IncLYEL | 5 | Buy | $44.00 | +298.55% | Reiterates | 2 months ago |
Tscan Therapeutics IncTCRX | 10 | Hold | N/A | N/A | Downgrades | 2 months ago |
Crispr Therapeutics AgCRSP | 29 | Buy | $82.00 | +59.47% | Reiterates | 2 months ago |
Faeth Therapeutics IncFTH | 1 | Buy | $56.00 | +199.63% | Initiates Coverage On | 2 months ago |
Mereo Biopharma Group PLCMREO | 22 | Buy | $3.00 | +938.06% | Reiterates | 3 months ago |
Taysha Gene Therapies IncTSHA | 35 | Buy | $12.00 | +190.56% | Maintains | 4 months ago |
Nkarta IncNKTX | 19 | Buy | $11.00 | +605.13% | Reiterates | 6 months ago |
Autolus Therapeutics PLCAUTL | 36 | Buy | $10.00 | +557.89% | Reiterates | 7 months ago |
Solid Biosciences IncSLDB | 4 | Buy | $19.00 | +206.45% | Reiterates | 7 months ago |
Immunocore Holdings PLCIMCR | 15 | Buy | $75.00 | +145.98% | Maintains | 8 months ago |
Arcellx IncACLX | 25 | Hold | N/A | N/A | Downgrades | 8 months ago |
Amicus Therapeutics IncFOLD | 7 | Hold | N/A | N/A | Downgrades | 10 months ago |
Fate Therapeutics IncFATE | 9 | Hold | N/A | N/A | Reiterates | a year ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | N/A | Reiterates | a year ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | N/A | Reiterates | a year ago |
Shattuck Labs IncSTTK | 15 | Hold | N/A | N/A | Reiterates | 2 years ago |
G1 Therapeutics IncGTHX | 18 | Hold | N/A | N/A | Downgrades | 2 years ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | 2 years ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 3 years ago |
Cti Biopharma CorpCTIC | 6 | Hold | N/A | N/A | Downgrades | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 4 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.